6291 Visiopharm Celebrates the Opening of Its New DACH Subsidiary in Germany

Danish-based leader in augmented pathology solutions Visiopharm has opened a new subsidiary in Germany to serve as the company’s headquarters in the DACH region.

The German office allows Visiopharm to meet its customers’ needs in an agile fashion and will be focused on driving business in the pharmaceutical and academic research fields, while further translating it into the healthcare and diagnostics sphere. 

Initially, the subsidiary will be staffed by three very experienced Digital Pathology veterans with experiences that span both research and diagnostics markets. Further growth of the subsidiary is expected by the fall of 2019.

“The DACH region has more segregated entities due to the federal healthcare system,” said Michael Grunkin Ph.D., CEO, and co-founder of Visiopharm. “Our German office will be focused on developing our capabilities to provide an enhanced service for them in particular, as we continue to demonstrate the value of digital pathology in academic research, healthcare and pharmaceutical development.”

Kai Remmert, DACH Sales Manager, will be heading up the office and brings a wealth of Digital Pathology sales expertise.

“I am delighted to join the team and lead the business from the new German office,” he said. “With my experience in the medical imaging industry, I see it a key strategic opportunity to drive the adoption of digital pathology through the region and achieve better patient outcomes as a result.”

The German office is in addition to Visiopharm’s head office in Medicon Valley, Copenhagen, and its further branch offices in the UK and Colorado, USA.

Following a €13.3 million investment in 2018 to fuel its international growth, Visiopharm is growing rapidly in both revenue and size. With a headcount approaching 100 employees, Visiopharm is the largest quantitative digital pathology company in the world.

Do you want to know more – contact us

Categories: Press Releases | Comments 6287 Visiopharm Welcomes Adrian Arechiga Arechiga as Chief Marketing Officer

Visiopharm is delighted to announce Adrian Arechiga Ph.D. as its new Chief Marketing Officer. Highly experienced as a Senior Marketing Director, Adrian has an impressive track record of working internationally in the biopharma, oncology diagnostics, and life science industries.

Adrian will be instrumental in leading Visiopharm’s marketing through its expansion following significant investment. He will be based in Visiopharm’s new office in Germany. 

“We are delighted to welcome such a talented and experienced Chief Marketing Officer to the company at this phase in our growth,” said Michael Grunkin Ph.D., CEO, and co-founder of Visiopharm. “Tissue image analysis is becoming increasingly important in drug-diagnostic co-development, and cancer diagnostics. With his strong scientific background, and practical experience in this field, Adrian is ideally positioned to communicate the benefits of this emerging and rapidly evolving technology, in a clear, concise and scientifically credible way, that has practical utility to scientists and pathologists.”

Adrian joins Visiopharm from Definiens, where he was the Senior Director of Global Brand and Product Marketing. He has over ten years’ experience working in the biotechnology, oncology diagnostics, and pharmaceutical industries, and holds a doctorate in Molecular Immunology and an MBA in Sustainable Management.

His role will initially be focused on strengthening the brand narrative and communicating digital pathology’s potential applications across tissue-diagnostics through a new content platform.
“I am excited to join Visiopharm, with a strong pipeline of new products and technologies, it Is a great time to join the team and communicate the value that Visiopharm delivers,” he said. “I look forward to developing our marketing capabilities and brand as we expand presence and market share globally.”

Following a €13.3 million investment in 2018 to fuel its international growth, Visiopharm is growing rapidly in both revenue and size. With a headcount approaching 100 employees, Visiopharm is the largest quantitative digital pathology company in the world.

Do you want to know more – contact us

Categories: Press Releases | Comments 6281 OracleBio incorporates Artificial Intelligence Deep Learning and High Multiplex Image Analysis Technologies to enhance Digital Pathology Capabilities

OracleBio Limited is pleased to announce the integration of Visiopharm’s Artificial Intelligence (AI) deep learning and phenotyping multiplexing modules into its existing Oncotopix® image analysis platform.

The Oncotopix® AI deep learning module allows OracleBio to access a range of the most up-to-date deep convolution neural networks for a more precise and robust classification of objects or regions of interest in tissue-based images. For example, these can include cell types, tumour regions, glomeruli, brain regions or any unique object or region.

Visiopharm’s Multiplex Phenotyping module streamlines and automates the analysis workflow of high multiplex image data, including image mass cytometry (IMC) multi-stack images. It offers a simultaneous analysis workflow of up to 255 channels, enabling tissue and cell segmentation for cell-based phenotyping.

The addition of Visiopharm’s AI deep learning and Multiplex Phenotyping modules will expand OracleBio’s capabilities and enable the company to:

“OracleBio strives to provide services at the forefront of Digital Pathology and this is signified by our continual efforts to adopt the latest innovations in the field” commented Lorcan Sherry, Chief Scientific Officer of OracleBio. “We have identified Visiopharm’s AI deep learning and phenotyping multiplexing modules as key technologies that will allow us to enhance image analysis capabilities, diversify the range of quantitative outputs, and ultimately improve study outcomes for our clients. Visiopharm is an industry leader in the Digital Pathology space and we are pleased to be extending our long-standing partnership with them.”

“We are very excited to partner with OracleBio, an innovative CRO that delivers superb digital analysis services” commented Adrian Arechiga, Chief Marketing Officer at Visiopharm. “This collaboration allows us to deliver unique digital pathology solutions to support pre-clinical and clinical research. Together, we will provide valuable insights to support outcomes and streamline decision making.”

Categories: Press Releases | Comments 6277 Visiopharm Welcomes Louise Armstrong as Chief Commercial Officer

Visiopharm Welcomes Louise Armstrong as Chief Commercial Officer 

Visiopharm is delighted to announce Louise Armstrong Ph.D. as its new Chief Commercial Officer. A Fellow of the Royal Society of Chemistry, Louise is highly experienced as a Life Science Commercial Director and has an impressive track record in business development in international markets.

Based in London, Louise brings extensive global sales skills with her and will be instrumental in driving Visiopharm’s rapid expansion following significant investment.

“Louise is a veteran of digital pathology, both within research, and on the commercial side, and brings a wealth of accomplishments with her to the Chief Commercial Officer role,” said Michael Grunkin Ph.D., CEO, and co-founder of Visiopharm. “She takes a consultative approach to sales – helping customers find the best possible solution for them – a value that makes her exceptionally well-aligned with the culture at Visiopharm.” 

Louise joins Visiopharm from Random 42, where she developed a commercial strategy for the private equity-backed medical animations agency and has previously driven global growth at Andor Technology as Global Sales Director. In her new role, she will be responsible for the company’s sales team worldwide.

It’s an exciting time to join Visiopharm,” she said. “With two decades of experience identifying and driving growth opportunities, this is an unmissable opportunity for me to support the company as it continues to grow its presence – and get its message and category-leading products out around the world. I’m looking forward to getting started.”

Following a €13.3 million investment in 2018 to fuel its international growth, Visiopharm is growing rapidly in both revenue and size. With a headcount approaching 100 employees, Visiopharm is the largest quantitative digital pathology software company in the world.

Do you want to know more – contact us

Categories: Press Releases | Comments
Success
Your message has been successfully sent!